Humoral immune response associated to the vaccines against SARS-CoV-2 in patients with rheumatic arthritis: data from the SAR-CoVAC registry

  • Carolina A. Isnardi Argentine Society of Rheumatology, Autonomous City of Buenos Aires, Argentina
  • Margarita Landi Austral University Hospital, Buenos Aires, Argentina
  • Natalia Laufer Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), Autonomous City of Buenos Aires, Argentina
  • Pablo Maid Austral University Hospital, Buenos Aires, Argentina
  • Claudia Calle Montoro Austral University Hospital, Buenos Aires, Argentina
  • Agustina Alfaro Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Brian Roldán Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Andrea Gómez Vara Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Pamela Giorgis Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Alejandro Ezquer Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • María G. Crespo Rocha Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Camila Reyes Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • María de los Ángeles Correa Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Osvaldo L. Cerda Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Marcos Rosemffet Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Virginia Carrizo Abarza Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Santiago Catalán Pellet Austral University Hospital, Buenos Aires, Argentina
  • Miguel Perandones Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Cecilia Reimundes Austral University Hospital, Buenos Aires, Argentina
  • Leonel Cruces University of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Yesica Longueira Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), Autonomous City of Buenos Aires, Argentina
  • Gabriela Turk Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), Autonomous City of Buenos Aires, Argentina
  • Florencia Quiroga Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), Autonomous City of Buenos Aires, Argentina
  • Rosana Quintana Argentine Society of Rheumatology, Autonomous City of Buenos Aires, Argentina
  • María Celina de la Vega Argentine Society of Rheumatology, Autonomous City of Buenos Aires, Argentina
  • Roberts Karen Argentine Society of Rheumatology, Autonomous City of Buenos Aires, Argentina
  • Gustavo Citera Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
  • Guillermo Pons Estel Argentine Society of Rheumatology, Autonomous City of Buenos Aires, Argentina
  • Emilce Schneeberger Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
DOI: https://doi.org/10.47196/rar.v32i4.508
Keywords: rheumatoid arthritis, COVID-19, COVID-19 vaccines

Abstract

Introduction: rheumatoid arthritis (RA) and its treatments can affect the response to the SARS-CoV-2 vaccine. However, we still do not have local data. Objectives: to evaluate the humoral response of the SARS-CoV-2 vaccine and its safety in this population. Materials and methods: observational study. Patients ≥18 years of age, with RA ACR/EULAR 2010 who had received vaccination for SARS-CoV-2 were included.

Author Biographies

Carolina A. Isnardi, Argentine Society of Rheumatology, Autonomous City of Buenos Aires, Argentina
Research unit
Margarita Landi, Austral University Hospital, Buenos Aires, Argentina
Rheumatology Service
Natalia Laufer, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), Autonomous City of Buenos Aires, Argentina
National Council for Scientific and Technical Research (CONICET). University of Buenos Aires, School of Medicine.
Pablo Maid, Austral University Hospital, Buenos Aires, Argentina
Rheumatology Service
Claudia Calle Montoro, Austral University Hospital, Buenos Aires, Argentina
Rheumatology Service
Agustina Alfaro, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Brian Roldán, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Andrea Gómez Vara, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Pamela Giorgis, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Alejandro Ezquer, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
María G. Crespo Rocha, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Camila Reyes, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
María de los Ángeles Correa, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Osvaldo L. Cerda, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Marcos Rosemffet, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Virginia Carrizo Abarza, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Santiago Catalán Pellet, Austral University Hospital, Buenos Aires, Argentina
Rheumatology Service
Miguel Perandones, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Cecilia Reimundes, Austral University Hospital, Buenos Aires, Argentina
Rheumatology Service
Leonel Cruces, University of Buenos Aires, Autonomous City of Buenos Aires, Argentina
School of Medicine
Yesica Longueira, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), Autonomous City of Buenos Aires, Argentina
National Council for Scientific and Technical Research (CONICET), University of Buenos Aires, School of Medicine.
Gabriela Turk, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), Autonomous City of Buenos Aires, Argentina
National Council for Scientific and Technical Research (CONICET), University of Buenos Aires, School of Medicine.
Florencia Quiroga, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), Autonomous City of Buenos Aires, Argentina
National Council for Scientific and Technical Research (CONICET), University of Buenos Aires, School of Medicine.
Rosana Quintana, Argentine Society of Rheumatology, Autonomous City of Buenos Aires, Argentina
Research unit
Roberts Karen, Argentine Society of Rheumatology, Autonomous City of Buenos Aires, Argentina
Research unit
Gustavo Citera, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section
Guillermo Pons Estel , Argentine Society of Rheumatology, Autonomous City of Buenos Aires, Argentina
Research unit
Emilce Schneeberger, Institute of Psychophysical Rehabilitation, Autonomous City of Buenos Aires, Argentina
Rheumatology Section

References

I. Ministerio de Salud de la Nación, 2021. Memorándum. Ampliación de la población objetivo a vacunar. Acceso 18/12/2021.

Disponible en: https://bancos.salud.gob.ar/recurso/memorandum-ampliacion-de-la-poblacion-objetivo-vacunar

II. Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021;80(10):1330-1338.

III. Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis 2021;80(10):1339-1344.

IV. Simon D, Tascilar K, Fagni F, Krönke G, Kleyer A, Meder C, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis 2021;80(10):1312-1316.

V. Ministerio de Salud de la Nación, 2021. Características de las vacunas contra la COVID-19 disponibles en Argentina. Acceso 18/12/2021. Disponible en:

https://bancos.salud.gob.ar/recurso/caracteristicas-de-las-vacunas-contra-la-covid-19-disponibles-en-argentina

VI. Ministerio de Salud de la Nación, 2021. Memorándum coadministración de vacunas contra COVID-19 con otras vacunas. Acceso 18/12/2021. Disponible en: https://bancos.salud.gob.ar/recurso/memorandum-coadministracion-de-vacunas-contra-covid-19-con-otras-vacunas

VII. Méndez H. Sociedad y estratificación. Método Graffar-Méndez Castellano. Caracas: Fundacredesa; 1994.

VIII. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-245.

IX. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569-2581.

X. Simader E, Tobudic S, Mandl P, Haslacher H, Perkmann T, Nothnagl T, et al. Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and sero-negative spondyloarthritis. Ann Rheum Dis 2021. doi: 10.1136/annrheumdis-2021-221347.

XI. Jena A, Mishra S, Deepak P, Kumar-M P, Sharma A, Patel YI, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev 2021;21(1):102927. doi: 10.1016/j.autrev.2021.102927.

XII. Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiede-berg K, Haller C, von Kempis J. Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. Lancet Rheumatol 2021;3(7):e470-e472. doi: 10.1016/S2665-9913(21)00186-7.

XIII. Ministerio de Salud de la Nación, 2021. 14º Informe de vigilancia de seguridad en vacunas. Acceso 18/12/2021.

Disponible en: https://bancos.salud.gob.ar/recurso/14o-informe-de-vigilancia-de-seguridad-en-vacunas

XIV. Ministerio de Salud de la Nación, 2021. Estudio colaborativo para la evaluación de esquemas heterólogos de vacunación contra COVID-19 en la República Argentina [ECEHeVac].

Disponible en: https://www.argentina.gob.ar/sites/default/files/2021/04/2021-08-13-avance-estudio-intercambiabilidad-vacunas-covid19-ecehevac.pdf

XV. Shenoy P, Ahmed S, Paul A, Cherian S, Vijayan A, Babu SA, et al. Inactivated vaccines may not provide adequate protection in immunosuppressed patients with rheumatic diseases. Ann Rheum Dis 2021. doi: 10.1136/ annrheumdis-2021-221496.

XVI. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv. Ann Intern Med 2021;174(11):1572-1585.

Published
2021-12-01
How to Cite
1.
Isnardi CA, Landi M, Laufer N, Maid P, Calle Montoro C, Alfaro A, Roldán B, Gómez Vara A, Giorgis P, Ezquer A, Crespo Rocha MG, Reyes C, Correa M de los Ángeles, L. Cerda O, Rosemffet M, Carrizo Abarza V, Catalán Pellet S, Perandones M, Reimundes C, Cruces L, Longueira Y, Turk G, Quiroga F, Quintana R, de la Vega MC, Karen R, Citera G, Pons Estel G, Schneeberger E. Humoral immune response associated to the vaccines against SARS-CoV-2 in patients with rheumatic arthritis: data from the SAR-CoVAC registry. Rev. Argent. Reumatol. [Internet]. 2021Dec.1 [cited 2025May11];32(4):7 - 16. Available from: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/508
Issue
Vol. 32 No. 4 (2021): October-December 2021
Section
Original Article

Copyright (c) 2021 Intellectual property rights: authors. Reproduction rights: Argentine Society of Rheumatology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.